Patient Voices at EHA 2026 Congress
Patient Voices at the EHA 2026 Congress by Hannah Mobarak, IWMF Global Partner Manager (pictured on far right with Dina Steagall and Prof. Shirley D’Sa) Stockholm, Sweden This year, the European Hematology Association brought the global hematology...
IWMF Welcomes New Grants and Contracts Administrator
A new team member joins IWMF The International Waldenstrom Macroglobulinemia Foundation (IWMF) is pleased to announce the addition of Kim Schwartz as its new Grants and Contracts Administrator. Kim’s Background Kim has over 6 years of experience in nonprofit...
Dana-Farber Establishes the Robert F. Tannenhauser Chair for Waldenström’s Research
A cure for WM is within reach, now more than ever The International Waldenstrom Macroglobulinemia Foundation (IWMF) is honored to share exciting news from Dana-Farber Cancer Institute: Dr. Steven P. Treon has been named the inaugural Robert F. Tannenhauser Chair for...
How Time Shapes Living with Waldenstrom (WM)
In WM, time isn’t just a measurement — it’s a strategy. This year, the European Educational Forum will explore how time shapes every stage of living with Waldenstrom Macroglobulinemia (WM) — from diagnosis and monitoring to treatment decisions and future therapies....
Being Brain Healthy: A March Webinar
with Marilyn Abrahamson, MA, CCC-SL Thursday, March 26th at 2:30pm EDT Join Marilyn Abrahamson, MA, CCC-SLP, a brain health coach, to learn evidence-based strategies to help improve mental clarity, attention, and cognitive stamina. This interactive IWMF webinar is...
NORD Breakthrough Summit 2025
From VOICES to BREAKTHROUGHS NORD® Breakthrough Summit 2025 October 19–21 | Washington, DC With Cyndi Powers, CMP This past week, I had the privilege of attending the NORD® Breakthrough Summit in Washington, DC, for the third time. Hosted by the National Organization...
Welcome Delora Senft as the New President & CEO of IWMF
Welcome Delora Senft as the New President & CEO of IWMF We’re excited to share that Delora Senft will be joining International Waldenstrom’s Macroglobulinemia Foundation (IWMF) as our new President and CEO on August 18. A Proven Leader in Cancer Research and Advocacy...
Into the world—Welcome Bexobrutideg!
Accelerate the Cure Into the world—Welcome Bexobrutideg! We recently wrote about a new type of drug—a BTK degrader— that emerged in 2024, for phase one trials at Nurix Therapeutics and BeOne. The Nurix trial earned FDA fast-track status in December. In a short three...